J. Fort

B. Lewis, G. Eisen, I. Gralnek, 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

B cell surface marker analysis of synovial fluid cells in a patient with monoarthritis and chronic lymphocytic leukemia.

C. Fernández, J. Fort, J. Abruzzo, 1992, The Journal of rheumatology.

Efficacy of celecoxib versus ibuprofen in the treatment of acute pain: a multicenter, double-blind, randomized controlled trial in acute ankle sprain.

E. Ekman, J. Fiechtner, J. Fort, 2002, American journal of orthopedics.

The budget impact of using enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg to prevent recurrent cardiovascular events

J. Tursi, D. Schofield, J. Fort, 2017, Journal of medical economics.

A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee.

G. Koch, T. Schnitzer, J. Jordan, 2001, Arthritis and rheumatism.

Celecoxib is associated with fewer small bowel lesions than naproxen+omeprazole in healthy subjects as determined by capsule endoscopy

B. Lewis, G. Eisen, I. Gralnek, 2003, American Journal of Gastroenterology.

Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis

A Gibofsky, G. Koch, R. Moskowitz, 2004, Annals of the rheumatic diseases.

Rofecoxib, but not celecoxib or naproxen, increases mean 24-hour systolic blood pressure in treated hypertensive patients with osteoarthritis and type 2 diabetes mellitus

B. Pitt, W. White, J. Sowers, 2003 .

Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.

W. White, A. Whelton, J. Puma, 2002, The American journal of cardiology.

Intravenous cyclophosphamide and methylprednisolone for the treatment of bronchiolitis obliterans and interstitial fibrosis associated with crysotherapy.

H. Scovern, J. Fort, J. Abruzzo, 1988, The Journal of rheumatology.

The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.

Thomas Brabant, Bertram Pitt, B. Pitt, 2005, Archives of internal medicine.

Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric‐coated aspirin 325 mg + immediate‐release omeprazole 40 mg) or enteric‐coated aspirin 325 mg + enteric‐coated omeprazole 40 mg – a randomised, phase 1, crossover study

P. Miner, J. Fort, Y. Zhang, 2013, Alimentary pharmacology & therapeutics.

Abstract 12057: Treatment Continuation and Cardiovascular Safety of Antiplatelet Therapy with PA32540, a Tablet With Enteric-coated Aspirin and Immediate-release Omeprazole: Results of Two 6-month, Phase 3 Studies

C. O'connor, D. Whellan, J. Scheiman, 2012 .

Clinical trial: evaluation of gastric acid suppression with three doses of immediate‐release esomeprazole in the fixed‐dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric‐coated esomeprazole 20 mg: a randomized, open‐label, Phase I study in healthy

M. Sostek, P. Miner, J. Plachetka, 2010, Alimentary pharmacology & therapeutics.

Efficacy and Safety of PA, a Novel Combination of Enteric-Coated Aspirin and Immediate-Release Omeprazole.

M. Alberts, J. Fort, C. Unal, 2009 .

Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec Osteoarthritis Study Group.

E. Tindall, A. Weaver, D. Sikes, 1998, The Journal of rheumatology.

Onset and durability of pain relief in knee osteoarthritis: Pooled results from two placebo trials of naproxen/esomeprazole combination and celecoxib

R. Holt, J. Kent, A. Grahn, 2015, The Physician and sportsmedicine.

Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials

M. Hochberg, C. Hwang, M. Sostek, 2011, Current medical research and opinion.

OR-25: Rofecoxib, but not celecoxib or naproxen, increases mean 24-hour systolic blood pressure: Results of a randomized double blind controlled trial in treated hypertensive patients with osteoarthritis (OA) and type 2 diabetes mellitus

B. Pitt, W. White, J. Sowers, 2003 .

Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial.

F. Mckenna, A. Gibofsky, J. Fort, 2003, Arthritis and rheumatism.

Celecoxib, a COX-2--specific inhibitor: the clinical data.

J. Fort, 1999, American journal of orthopedics.

SAT0094 Celecoxib does not increase the risk of cardiac failure, oedema, or hypertension compared to nsaids: results from success 1, a double blind, randomised trial in 13,274 oa patients

W. White, A. Whelton, G. Singh, 2001 .

COX-2 Specific Inhibitors in the Management of Osteoarthritis of the Knee: A Placebo-Controlled, Randomized, Double-Blind Study

J. Fiechtner, F. Mckenna, A. Weaver, 2001, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

Significantly improved upper gastrointestinal (UGI) telerability with celecoxib, a COX-2 specific inhibitor, compared with conventional NSAIDs. The SUCCESS I trial

G. Eisen, W. Stenson, J. Goldstein, 2001 .

(763): Alvimopan, a novel peripherally acting mu-opioid receptor antagonist, does not affect opioid-based, centrally mediated analgesia following surgery

E. Viscusi, L. Techner, J. Leslie, 2006 .

Modified Severity of Dyspepsia Assessment pain scale: a new tool for measuring upper abdominal pain in osteoarthritis patients taking NSAIDs

R. Dickerhoof, B. Cryer, J. Crawley, 2011, Patient Related Outcome Measures.

Economic and gastrointestinal safety comparisons of etodolac, nabumetone, and oxaprozin from insurance claims data from patients with arthritis.

S. Z. Zhao, S. Dedhiya, L. Simon, 1998, Clinical therapeutics.

CLINICAL FOCUS: RHEUMATOLOGY, PAIN MANAGEMENT AND CONCUSSION GUIDELINES ORIGINAL RESEARCH Onset and durability of pain relief in knee osteoarthritis: Pooled results from two placebo trials of naproxen/esomeprazole combination and celecoxib

R. Holt, J. Kent, A. Grahn, 2015 .

Can tests for IgA, IgG, or IgM antibodies to cardiolipin or phosphatidylserine substitute for lupus anticoagulant assays in screening for antiphospholipid antibodies?

J. Fort, F. Cowchock, 1994, Autoimmunity.

P. Miner, Ying Zhang, J. Fort, 2013, Alimentary pharmacology & therapeutics.

Abnormal small bowel findings are common in healthy subjects screened for a multi-center, double blind, randomized, placebo-controlled trial using capsule endoscopy

B. Lewis, N. Arber, J. Johanson, 2003 .

Significant reduction in serious upper gastrointestinal (UGI) events with celecoxib, a COX-2 specific inhibitor, compared with conventional NSAIDs. The SUCCESS I trial

G. Eisen, W. Stenson, J. Goldstein, 2001 .